1.COPD. World Health Organization (2017)
2.Burden of COPD. World Health Organization
3.BPCO: dati epidemiologici. Ministero della Salute (ultimo aggiornamento Novembre 2019)
4.Rogliani P. et al. Adherence to COPD treatment: Myth and reality. Respiratory Medicine (2017); 129: 117-123
5.Humenberger M et al. Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD). BMC Pulmonary Medicine (2018); 18:163
6.Bourbeau J and Bartlett SJ. Patient adherence in COPD. Thorax (2008); 63:831–838
7.Jardim JR and Nascimento OA. The Importance of Inhaler Adherence to Prevent COPD Exacerbations. Med. Sci. (2019), 7: 54
8.Chrystyn H. et al. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respiratory Medicine (2014); 108: 358-365
9.Bettoncelli G. Importanza del device nella terapia inalatoria dell’asma e della BPCO. Rivista Società Italiana di Medicina Generale (2016); 6
10.van der Palen J. et al. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. International Journal of COPD (2018);13: 2515–2523
11.Komase Y. et al. Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older. International Journal of COPD (2014);9: 1365–1375